Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer

Cancer Science

Volumn 104, Issue 1, 2013, Pages 116-123

  Kim, Su Jung ^a,b   Kim, Yu Jung ^a   Kim, Jee Hyun ^a   Park, Do Joong ^a   Kim, Hyung Ho ^a   Lee, Jong Seok ^a   Lee, Keun Wook ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BRAIN INFARCTION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PATIENT COMPLIANCE; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 84872278330     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12044     Document Type: Article

References (16)

1. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-15.
2. Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A.Gastric Cancer Working Group report. Jpn J Clin Oncol 2010; 40 (Suppl. 1): i28-37.
3. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20.
4. Sasako M, Sakuramoto S, Katai H et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-93.
5. Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009; 39: 2-15.
6. Sakuma K, Hosoya Y, Arai W et al. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. Int J Clin Oncol 2010; 15: 166-71.
7. Iwasa S, Yamada Y, Fukagawa T et al. Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer 2011; 14: 28-34.
8. Aoyama T, Yoshikawa T, Hayashi T et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer 2012; doi: 10.1007/s10120-012-0158-1 [Epub ahead of print].
9. Aoyama T, Yoshikawa T, Watanabe T et al. Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients. Gastric Cancer 2012; 15: 76-82.
10. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3758 patients. Cancer Chemother Pharmacol 2008; 61: 335-43.
11. Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24.
12. CTCAE, Cancer Therapy Evaluation Program: Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS, 2003. [Cited 5 August 2011.] Available from URL: http://ctep.cancer.gov
13. CTCAE, Common Terminology Criteria for Adverse Events version 4.0, 2010. [Cited 5 August 2011.] Available from URL: http://evs.nci.nih.gov/ftp1/CTCAE/About.html
14. Sakuramoto S, Kikuchi S, Watanabe M. Efficacy of S-1 (oral fluoropyrimidine) for gastric cancer. The Medical Frontline (Saishin Igaku) 2009; 64: 1075-80.
15. Fujita K, Yamamoto W, Endo S et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 2008; 99: 1049-54.
16. Ikeda M, Furukawa H, Imamura H et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 2002; 50: 25-32.